Skip to main content

Table 2 Tumor characteristics according to HER2 status

From: HELENA: HER2-Low as a prEdictive factor of response to Neoadjuvant chemotherapy in eArly breast cancer

 

HER2 1 + 

HER2 2 + 

p-value

N = 160

N = 77

 

Variable

n

%

N

n

%

N

 

SBR grade

  

160

  

77

0.48

 I

5

3.1

 

1

1.3

  

 II

69

43.1

 

39

50.6

  

 III

86

53.8

 

37

48.1

  

ER IHC expression

  

160

  

77

0.58

  < 10%

57

35.6

 

31

40.3

  

  ≥ 10%

103

64.4

 

46

59.7

  

PR IHC expression

  

160

  

77

0.79

  < 10%

89

55.6

 

45

58.4

  

  ≥ 10%

71

44.4

 

32

41.6

  

Ki67 IHC expression

  

121

  

55

0.44

  ≤ 20%

27

22.3

 

16

29.0

  

  > 20%

94

77.7

 

39

71.0

  

Lymphovascular embolism

  

112

  

54

0.95

 Yes

29

25.9

 

13

24.1

  

 No

83

74.1

 

41

75.9

  
  1. With HER2 Human epidermal growth factor receptor 2, SBR Scarff-Bloom and Richardson, ER Estrogen receptor, PR Progesterone receptor, IHC Immunohistochemistry
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us